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Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC
GEF activity and contributes to BCR-ABL leukemogenesis
S Gerboth1,9, E Frittoli1,9, A Palamidessi1, FC Baltanas2,10, M Salek1,11, J Rappsilber1,12, C Giuliani1, F Troglio1, Y Rolland1, G Pruneri3,
S Kreutmair4, I Pallavicini3, M Zobel1, M Cinquanta5, S Minucci3,4, C Gomez2, E Santos2, AL Illert6,7 and G Scita1,8
Son of Sevenless 1 (SOS1) is a dual guanine nucleotide exchange factor (GEF) that activates the small GTPases RAC and RAS.
Although the molecular mechanisms of RAS GEF catalysis have been unveiled, how SOS1 acquires RAC GEF activity and what is the
physio-pathological relevance of this activity is much less understood. Here we show that SOS1 is tyrosine phosphorylated on
Y1196 by ABL. Phosphorylation of Y1196 controls SOS1 inter-molecular interaction, is required to promote the exchange of
nucleotides on RAC in vitro and for platelet-derived growth factor (PDGF) activation of RAC- and RAC-dependent actin remodeling
and cell migration. SOS1 is also phosphorylated on Y1196 by BCR-ABL in chronic myelogenous leukemic cells. Importantly, in these
cells, SOS1 is required for BCR-ABL-mediated activation of RAC, cell proliferation and transformation in vitro and in a xenograft
mouse model. Finally, genetic removal of Sos1 in the bone marrow-derived cells (BMDCs) from Sos1ﬂ/ﬂ mice and infected with BCR-
ABL causes a signiﬁcant delay in the onset of leukemogenesis once BMDCs are injected into recipient, lethally irradiated mice. Thus,
SOS1 is required for full transformation and critically contribute to the leukemogenic potential of BCR-ABL.
Leukemia advance online publication, 12 September 2017; doi:10.1038/leu.2017.267
KEY POINTS
● ABL-mediated phosphorylation of Y1196 SOS1 elicits its RAC
GEF activity in vitro and in vivo.
● A SOS1pY1196-RAC axis delays the onset of BCR-ABL
leukemogenesis.
INTRODUCTION
Son of Sevenless 1 (SOS1) has a central role in signal transduction
from receptor tyrosine kinases (RTKs) to small G proteins RAS
and RAC.1–4 Structural and biochemical studies revealed that SOS1
is a multi-domains protein with extensive intramolecular interaction
that tightly constrains its activity.5 For example, SOS1 possesses two
binding sites for RAS, one of which is an allosteric site that is distal
to the active one.6 Binding of active RAS at this site stimulates the
nucleotide-exchange activity of SOS1 by causing conformational
changes that allow substrate RAS to bind.2,7–9
An additional important domain is the DH-PH (Dbl and
Pleckstrin Homology domain), which is a structural hallmark for
exchange factors of the Rho family of GTPases, and was proposed
to act as a RAC-speciﬁc guanine nucleotide exchange factor
(GEF).10–20 However, the DH-PH unit is folded into a closed
conformation, implying that SOS1 RAC GEF activity is auto-
inhibited and requires speciﬁc molecular events to be
activated.8,21,22 Two distinct mechanisms of SOS1 activation have
been proposed: SOS1 must assemble into a multimolecular
complex with EPS8, ABI1 to become catalytically active.12,17–20
The second mechanism, instead, involves tyrosine phosphoryla-
tion of SOS1 by ABL kinase.15 However, how tyrosine phosphor-
ylation induces SOS1 RAC GEF activity and its pathophysiological
relevance remains ill deﬁned.
Physiologically, ABL kinase participates in RTK-induced actin
cytoskeleton remodeling, a signaling pathway in which the
function of the SOS1-RAC axis is pivotal.15 Hyperactive, uncon-
trolled kinase activity of ABL is also responsible for its oncogenic
potential. The p210-BCR-ABL fusion oncoprotein is indeed
necessary and sufﬁcient to cause chronic myelogenous
leukemia.23,24 Although the role of BCR-ABL in chronic myelogen-
ous leukemia has been well studied, the critical signaling
pathways mediating its transforming ability are incompletely
clariﬁed. Among them, the one leading to the activation of RAC
GTPases critically mediates BCR-ABL transformation.25–27 Indeed,
RAC3, one of the three mammalian RAC isoforms, is activated in
p190-BCR-ABL malignant precursor B-lineage lymphoblast and its
removal increases survival in p190-BCR-ABL-transgenic, RAC3-null
mice (a model of acute lymphoid leukemia).28 In addition, the
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ubiquitously expressed RAC1 and hematopoietic-restricted RAC2
were shown to be critical for p210-BCR-ABL-mediated leukemo-
genesis and myeloproliferative disease.29 How RAC becomes
activated by ABL thus becomes a key question to be addressed.
SOS1, which is expressed in myeloid cells and is regulated by
ABL,15 may serve this role.
Here we show that phosphorylation of Y1196 on the C-terminal
proline-rich region of SOS1 is sufﬁcient to elicit its RAC GEF activity
in vitro and in vivo in response to the activation of various receptor
and non-RTKs, including ABL. We further demonstrate that Y1196
of SOS1 is phosphorylated in BCR-ABL leukemic human and
murine blasts, and is required for full RAC activation, cell
proliferation and transformation in vitro and in mouse models.
Genetic removal of SOS1 delays the onset of BCR-ABL
leukemogenesis.
MATERIALS AND METHODS
Materials and methods are described in details in Supplementary
Information.
RESULTS
SOS1 is tyrosine phosphorylated on Y1196 in vitro
To investigate the molecular, biochemical and functional con-
sequences of ABL-mediated tyrosine phosphorylation of SOS1 we
sought to identify the target tyrosine(s). As an initial approach, we
subjected full-length SOS1 and various recombinant shorter
fragments to an in vitro kinase assay with ABL kinase
(Supplementary Figure S1A (top)). Only the fragment encompass-
ing the C-terminal proline-rich region was efﬁciently tyrosine
phosphorylated (Supplementary Figure S1A), hence restricting the
region targeted by ABL.
Next, we used in vitro tyrosine phosphorylated SOS1 and
titanium oxide-based afﬁnity chromatography to enrich for
phosphorylated peptides coupled with nano liquid chromatogra-
phy–tandem mass spectrometry analysis30,31 (Figure 1a). We
generated a peak list, which was searched against the IPI human
database using Mascot 2.0 (Matrix Science Inc., Boston, MA, USA).
However, no pY-containing peptide could be identiﬁed auto-
matically by Mascot search, but spotted instead by searching the
MS/MS data set for pTyr immonium ion at m/z 216.043(refs 32,33)
Figure 1. Tyrosine 1196 of SOS1 is the major target residue of ABL kinase. (a) SOS1 immuno-puriﬁed from SOS1-expressing 293T cells (1 mg
lysates) with an anti-SOS1 antibody was in vitro phosphorylated with ABL kinase, resolved on SDS-Page and detected by Coomassie staining
or by immunoblotting (IB) using the indicated antibody. SOS1 band was digested with trypsin. Phosphorylated peptides were enriched with
titanium oxide beads and analyzed by tandem mass spectrometry. Left: the diagram shows the detected fragments of the phosphorylated
pYSISDR peptide. Fragments are presented according to their mass/charge ratio (m/z) and their intensity (relative abundance). The intensity of
the highest peak corresponds to a relative abundance of 100%. Right: The possible fragmentation of the peptide is shown. The peak (pY) in
the diagram (left) with an m/z of 216,07 corresponds to the a1 fragment on the right. Mw markers are indicated on the side of the
immunoblots. (b) WT-SOS1 and Y1196F-SOS1 immunopuriﬁed from SOS1-overexpressing 293T cells (1 mg lysate) were incubated in the
presence or absence (Control) of ABL kinase and 32P-ATP and subjected to SDS-polyacrylamide gel electrophoresis. After PonceauS staining,
the SOS1 band was excised and digested with trypsin. Oxidized peptides were separated by electrophoresis and thin layer chromatography.
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and subsequently sequenced manually. This procedure revealed
Y1196, located in the proline-rich C-terminus of SOS1, as the major
putative ABL kinase target (Figure 1a). We validated this result
using two-dimensional phospho-peptide mapping that revealed a
single, major phosphorylated spot derived from WT-SOS1, but not
from Y1196F-SOS1 mutant (Figure 1b). Thus, tyrosine 1196 is the
major ABL phosphorylation site of SOS1 in vitro.
SOS1 is tyrosine phosphorylated on Y1196 in vivo
To assess whether Y1196 is phosphorylated in vivo, we undertook
two distinct approaches. First, we ectopically expressed WT-SOS1
or Y1196F-SOS1 mutant in combination with an activated form of
ABL (ABL-ΔSH3)34 in 293T cells. Immunoblotting with anti-pY
antibodies of SOS1 immunoprecipitates revealed that tyrosine
phosphorylation of Y1196F-SOS1 was signiﬁcantly reduced with
respect to WT-SOS1 (Supplementary Figure S1C). Next, we raised
monoclonal, anti-pY1196 antibodies the speciﬁcity of which was
tested using WT- and Y1196-SOS1 in various assays
(Supplementary Figures S2A and B). We detected Y1196
phosphorylation in lysates of cells expressing activated ABL and
WT-SOS1, but not Y1196F-SOS1 mutant, both when we immuno-
precipitated total SOS1 with anti-hemagglutinin (HA) antibody,
followed by immunoblotting with anti-pY1196 or vice versa
(Supplementary Figure S3A). In addition, as SOS1 and ABL act on
RTK-dependent signaling pathways,15,35,36 we found that platelet-
derived growth factor (PDGF) stimulation efﬁciently phosphory-
lated endogenous SOS1 on Y1196 in mouse embryo ﬁbroblasts
(MEFs) (Supplementary Figure S3B). Similarly, stimulation of ERBB
family members with either Heregulin or epidermal growth factor
in breast cancer cell lines increased Y1196-SOS1 phosphorylation,
which was abrogated by the ABL kinase inhibitor Imatinib (STI571)
(Supplementary Figure S3B). We concluded that phosphorylation
of Y1196 occurs physiologically in response to a variety of RTK-
dependent stimuli, presumably through ABL kinase activity.
Phosphorylation of Y1196 is sufﬁcient to promote the exchange of
nucleotides on RAC1, but not on H-RAS in vitro
Next, we tested GEF activities on RAC1 and H-RAS of tyrosine-
phosphorylated SOS1. Tyrosine-phosphorylated SOS1, puriﬁed
from cells co-expressing activated ABL, but not Y1196F-SOS1
mutant, displayed detectable RAC1-GEF activity in in vitro assays
(Supplementary Figures S4A and B). Importantly, under the same
conditions, WT- and Y1196F-SOS1 showed similar levels of H-RAS-
GEF activity, indicating that tyrosine phosphorylation speciﬁcally
affects RAC1, but not H-RAS-GEF activity (Supplementary
Figure S4A). To conﬁrm that the Y1196F mutation abrogates
ABL-mediated SOS1 RAC1 GEF activity, we performed a double
afﬁnity puriﬁcation of SOS1 from lysates of cells expressing
activated ABL and SOS1 using a GRB2-GST column in tandem with
an anti-pY1196 antibody-protein G-sepharose column
(Supplementary Figure S4C). The ﬁnal elution step with phos-
phorylated antigenic SOS1 peptides yielded highly puriﬁed
pY1196-SOS1 (Supplementary Figure S4C). Using a ﬂuorescent-
nucleotide-based RAC1-GEF assay, we showed that pY1196-SOS1
promoted guanine nucleotide exchange on RAC1 at catalytic
concentrations, similar to the DH-PH domain of TIAM1, used as
positive control (Figure 2a). Finally, dephosphorylation of pY-SOS1
with a tyrosine-speciﬁc phosphatase abrogated its RAC1-GEF
activity (Figure 2b). Thus, tyrosine-phosphorylated SOS1 acts as a
RAC1-GEF in vitro.
SOS1 inter-molecular interaction is inhibited by activated ABL
These ﬁndings raise the question as to the underlying molecular
mechanism. Crystallization studies revealed that SOS1 is engaged
into extensive intra-molecular and possibly inter-molecular
interactions.8,37 However, none of the solved structures of SOS1
includes the proline-rich region, which contains Y1196. We
hypothesized that also this region undergoes intramolecular or
intermolecular interactions with other SOS1 domains. We initially
tested the ability of various, immobilized SOS1 fragments to bind
the soluble proline-rich region in far western assays. We found
that SOS1 proline-rich region binds with a micromolar (apparent)
afﬁnity to its DH-PH domain and further restricted the region of
interaction to the PH domain (Supplementary Figures S5A–C). The
SOS1 PH domain has been proposed to exert an inhibitory effect
on the DH domain by blocking its accessibility to RAC1.22
A signiﬁcant change in the fold must therefore be invoked for
this domain to become catalytically active. Loss of binding of the
proline-rich region to the DH-PH domain may be implicated in
initiating these structural changes. We thus performed a binding
assay between the DH-PH domain and either the phosphory-
lated or a non-phosphorylated Y1196-containing peptide. The
phosphorylated peptide bound the DH-PH domain with a much
lower apparent afﬁnity (Kd4200 μM), as compared with the non-
phosphorylated peptide (Kd ~ 30 μM) (Supplementary Figure S5D).
These ﬁndings are also compatible with the possibility of trans
rather than cis interaction between two SOS1 molecules, where
the proline-rich region of one molecule may bind to the DH-PH
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Figure 2. Phosphorylation of Y1196 by ABL is sufﬁcient to elicit SOS1 RAC GEF activity. (a and b). MANT-GDP-ﬂuorescence RAC GEF assay of
puriﬁed pY1196F-SOS1. GST-RAC1 was equilibrated with 2 μM MANT-GDP. After 300 s, we added: (b) puriﬁed, phospho-enriched SOS1 (30 μl
and 120 μl, corresponding to ~ 10 and 40 nM, respectively) or 50 nM of His-DH-PH of Tiam1 (used as positive control). Buffer indicates the non-
stimulated nucleotide exchange rate of RAC1; left panels, puriﬁed, phospho-enriched SOS1 or un-phosphorylated SOS1 (treated with T-cell-
speciﬁc tyrosine phosphatase either in the presence (TCI) or the absence (TC) of T-cell phosphatase inhibitor). The reaction containing MANT-
GDP was excited at 360 nm. The emission of MANT-GDP-bound to RAC was measured at 440 nm. Right panels: aliquots of phosphorylated
(TCI) and phosphatases dephosphorylated (TC) SOS1 was immunoblotted with the antibodies indicated on the right.
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domain of the other. If this was the case, then a fraction of SOS1
may form dimers, as previously suggested,37 whose stability
should be controlled by Y1196 phosphorylation. Consistently, by
exploiting differentially HA- and green ﬂuorescent protein (GFP)-
tagged SOS1 constructs, we showed that: (i) a sizable fraction of
HA-tagged SOS1 co-immunoprecipated with GFP-SOS1
(Supplementary Figure S5E); (ii) the concomitant expression of
an activated ABL robustly reduced this inter-molecular interaction
(Supplementary Figure S5E); and (iii) mutation of Y1196F that
prevents ABL-mediated phosphorylation and the acquisition of
RAC1-GEF activity also inhibited the inter-molecular interaction
(Supplementary Figure S5F). These results indicate that SOS1
needs to be in its tyrosine phosphorylated, monomeric form to act
as RAC1 GEF. A corollary of this mode of action is that a SOS1-
Y1196F mutant should not only be deﬁcient in RAC1 activation
in vitro (as we showed above), but may also act as a dominant
negative. Consistently, the expression of SOS1-Y1196F completely
inhibited RAC1-GTP levels in SOS1 proﬁcient cells, acting in a
dominant-negative manner (Supplementary Figure S5G).
Although more work is needed to precisely decipher the
sequence of molecular events, the sum of this ﬁnding indicates
that tyrosine phosphorylation of Y1196 promotes the dissociation
of SOS1 inter-molecular interaction, resulting in the formation of
monomers which, either alone or through subsequent incorpora-
tion into larger molecular weight complexes (see Discussion),
leads to optimal activation of SOS1 RAC1-GEF.
Phosphorylation of SOS1 Y1196 is required for optimal PDGF-
dependent activation of RAC1, RAC1-dependent actin remodeling
and migration
To validate the physiological relevance of Y1196 phosphorylation
of SOS1 in controlling the activation of RAC, we measured the
cellular levels of GTP-bound RAC. Initially, we used cells co-
expressing either WT- or Y1196F-SOS1 together with activated
ABL. Activated ABL increased RAC1-GTP levels, which are not
signiﬁcantly altered by the concomitant expression of SOS1,
indicating that the latter protein is not a limiting factor in this
pathway (Supplementary Figure S6A). Conversely, co-expression
of activated ABL and Y1196F-SOS1 robustly reduced ABL-
mediated RAC activation (Supplementary Figure S6A), consistent
with Y1196F-SOS1 exerting a dominant-negative function.
Next, we assessed whether this posttranslational modiﬁcation
had an impact on RAC activation in response to PDGF
stimulation15,35 using Sos1− /− MEFs reconstituted with either
WT- or Y1196F-SOS1 (Supplementary Figure S6B). Sos1− /− MEF
showed reduced RAC-GTP levels as compared with Sos1− /− MEF
reconstituted with WT-SOS1 (Figure 3a). Conversely, the expres-
sion of Y1196F-SOS1 did not restore RAC activation (Figure 3a).
Notably, PDGF-induced ERK and AKT activities were unaffected by
either SOS1 removal or the expression of Y1196F-SOS1 mutant
(Supplementary Figure S6C). In agreement with the observation
that pY1196 of SOS1 mediates not only RAC activation, but also
PDGF-induced, RAC-dependent actin remodeling, Sos1− /− MEFs
were impaired in the formation of PDGF-induced circular dorsal
rufﬂes (Figure 3b), where SOS1 localizes (Supplementary
Figure S6D). Circular dorsal rufﬂes are RAC-dependent migratory
and endocytic structures that mark the acquisition of a
mesenchymal mode of cell locomotion.38 This response was
restored by WT-SOS1, but not Y1196F-SOS1 (Figure 3b). Notably,
Y1196F-SOS1 expression not only failed in rescuing circular dorsal
rufﬂe, but also inhibited their formation (Figure 3b). The speciﬁc
requirement of SOS1 as a RAC-GEF in PDGF-induced actin
remodeling is underscored by the ﬁnding that functional
interference with VAV, a RAC-GEF family protein regulated by
tyrosine phosphorylation, had no effect on circular dorsal rufﬂe
formation (Supplementary Figure S6E). Finally, Sos1− /− MEFs
were impaired in cell motility, which was increased by the
expression of WT, but not of Y1196-SOS1 (Supplementary
Figure S6F and Supplementary Movie S1). Thus, SOS1 and
phosphorylation of Y1196 are required for optimal RAC1 activation
and RAC1-dependent actin remodeling and cell motility in
response to PDGF stimulation.
SOS1 is phosphorylated by oncogenic BCR-ABL in leukemic blast
and is required for BCR-ABL-mediated full transformation
We next assessed whether phosphorylation of SOS1 Y1196 might
also be critical in pathological conditions characterized by a
hyperactive ABL kinases activity. The fusion oncoprotein BCR-ABL
originating from a balance chromosome translocation leading to
chronic myelogenous leukemia is a case in point.39 Among BCR-
ABL-stimulated oncogenic pathways the one leading to activation
of RAC proteins has been shown to be pivotal for full
transformation.25,29,40 We thus tested whether SOS1 contributes
to BCR-ABL-mediated RAC activation and transforming potential.
Using pY1196-phospho-speciﬁc antibody, we showed that SOS1 is
tyrosine phosphorylated in K562, a human cell line derived from a
chronic myelogenous leukemia patient, and in BCR-ABL-
expressing murine hematopoietic progenitor 32D cell line
(Supplementary Figures S7A and B). The administration of the
ABL kinase inhibitor STI571 abolished SOS1 phosphorylation in
both cell lines (Supplementary Figure S7B). Next, we generated
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Figure 3. Phosphorylation of SOS1-Y1196 is required to promote
optimal RAC activation, RAC-dependent actin remodeling in
ﬁbroblasts in response to PDGF. (a) Wild type, but not Y1196F-
SOS1, reconstitutes RAC activation in Sos1− /− MEFs. Serum-starved
Sos1− /− MEFs, reconstituted with HA-WT-SOS1 or HA-Y1196F-SOS1
(YF) or empty vector, as control (Ctr) (see Supplementary
Figure S6A), were stimulated with 10 ng/ml of PDGF for 7 min.
Activated RAC-GTP was pulled down from 1 mg of total lysates
using 20 μg of recombinant GST-CRIB. Lysates (20 μg) and bound
proteins were immunoblotted with the indicated antibodies.
(b) Serum-starved Sos1− /− MEFs, reconstituted with HA-WT-SOS1
or HA-Y1196F-SOS1 or empty vector (Ctr), were stimulated with
10 ng/ml of PDGF for 7 min. Cells were stained for F-actin with Tritc-
Phalloidine. The number of cells with circular dorsal rufﬂe (CDR) is
expressed as percent of total. At least 100 cells were scored for each
condition. The data represents the mean± s.e.m (n= 4 performed in
triplicates). Right panels: representative pictures of MEFs forming
CDR. Scale bar, 40 μm.
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K562 cells stably knocked down for SOS1 (SOS1-KD) with three
independent short hairpin RNAs (see also Supplementary
Methods). SOS1 silencing reduced RAC-GTP levels, similar to
STI571 treatment (Figure 4a), but had no impact on ERK1/2 activity
(Supplementary Figure S7C). In addition, SOS1-KD K562 cells had a
signiﬁcantly reduced rate of proliferation compared with
scramble-transfected control cells (Figure 4b), but similar to the
one achieved by treatment with the RAC inhibitor, NSC27633
(Figure 4b). Notably, treatment with STI571 was, as expected,39
more effective in reducing cell proliferation (Figure 4b), also as a
consequence of increase cell death, which instead was not
observed after SOS1 removal or RAC inhibition (Supplementary
Figure S7D). The slower proliferation rate of SOS1-KD K562 cells
was also accompanied by increased expression of hemoglobin, a
prototypical erythroid marker (Supplementary Figure S7E).
Next, we tested weather SOS1 ablation impairs transformation
and tumorigenesis. In soft agar growth assays, under conditions in
which STI571 treatment completely abrogated transformation,
SOS1 silencing signiﬁcantly reduced both the number and the size
of colony as compared with untreated, control K562 cells
(Figure 4c). In xenotransplantation mouse model, NOD/SCID mice
injected with control K562 rapidly died due, as expected
(Figure 4d), to the expansion of leukemic blasts (not shown).
The removal of SOS1 from K562 cells drastically increased mice
survival (Figure 4d).
To provide direct evidence that the above phenotypic
alterations are caused by the loss of Sos1 and of Y1196
phosphorylation, we restored the expression of either WT- or
Y1196F-SOS1 mutant into SOS1-KD K562 cells using short hairpin
RNA-resistant variants fused to GFP. GFP-WT and GFP-Y1196F-
SOS1 expression levels were comparable to those of endogenous
SOS1 of control K562, whereas endogenous SOS1 levels in the
ectopically reconstituted cells remain signiﬁcantly downregulated
(Supplementary Figure S8A). Re-expression of WT-SOS1, but not of
Y1196F-SOS1 mutant, reduced hemoglobin, suggesting that
differentiation blockade was restored (Supplementary
Figure S8A), restored RAC-GTP levels (Supplementary
Figure S8B), cell proliferation (Supplementary Figure S8C) and
transformation potential (Supplementary Figure S8D).
The transient nature of SOS1 knocked down and Y1196F re-
expression, which were counter selected and lasted only for a
limited number of passages (similar data were obtained using
CRISPR-SOS1-KO K562 cells—not shown), prevented us to assess
whether also in vivo we could restore leukemogenesis. To
overcome this limitation, we employed a murine model in which
the loss of Sos1 can be induced by tamoxifen-mediated CRE
recombination (herein on referred to as Sos1ﬂ/ﬂ).41 bone marrow-
derived cell (BMDC) from control and Sos1ﬂ/ﬂ mice were retro-
virally infected with EGFP-p210-BCR-ABL-fusion gene-expressing
retroviral vectors (MigBCR-ABLp210), treated with tamoxifen to
induce Sos1 deletion and tested in vitro and in vivo to assess BCR-
ABL transforming and leukemogenic ability (Figure 5). Consistent
with the results obtained with human K562 cells, genetic removal
of Sos1 signiﬁcantly reduced colony formation (Supplementary
Figure S9A), without altering the immunophenotypes of BCR-ABL-
transformed Sos1 null BMDC as compared with control cells
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Figure 4. SOS1 phosphorylation is required for RAC1 activation and BCR-ABL-mediated full transformation. (a) K562 cells infected with
pSuperRetroPuro Control vector (Ctr) or pSuperRetroPuro SOS1 interfering vector (SOS1-KD) were treated for 10 min with 10 μM STI571 or
vehicle as control (Ctr). We used three independent short hairpin RNA (shRNA) to generate three mass SOS1-KD populations (see
Supplementary Methods), which gave similar results. Cell Lysates were incubated for 1 h with 20 μg of GST-CRIB to pull down GTP-loaded RAC
and immunoblotted to detect activated RAC. (b) An equal number (50 000 cells/ml) of K562 control cells (Ctr), STI571-treated, NSC2376-
treated or SOS1-KD cells (SOS1 KD) were plated and counted at the indicated times. Data are the mean± s.e.m. of four independent
experiments done in triplicates. (c). An equal number (100 000 cells/ml) of control (Ctr), or STI571-treated or SOS1-KD K562cells (SOS1 KD)
were plated in soft agar. Upper panels, representative pictures of the colonies obtained after 14 days. Lower graphs, quantiﬁcation of colony
number (left) and colony diameter (right). At least 50 colonies were counted. Data are the mean± s.e.m (n= 3 independent experiments).
**Po0.005 Student’s t-test. Scale bar, 200 μm. (d) An equal number (5 × 105) of control and SOS-1 KD K562 were injected into the tail vein of
immunodeﬁcient mice. Mice were monitored for survival (n= 15 of a representative experiment run in duplicate). P-values (Pearson) were
measured by χ2-test.
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(Supplementary Figure S9A). More relevantly, tamoxifen-mediated
Sos1 loss of BCR-ABL-infected Sos1ﬂ/ﬂ BMDC signiﬁcantly delayed
the development of leukemia upon BMDC transplantation into
recipient mice (Figures 5a-c), without affecting engraftment
(Supplementary Figures S9B and C) and stemness potential of
the leukemic cells (Supplementary Figures S9E–G).
Collectively, our result supports the notion that SOS1 is
phosphorylated by oncogenic BCR-ABL in leukemic cells, is
required for BCR-ABL-mediated full transformation and contri-
butes to leukemogenesis.
DISCUSSION
In this work, we provide evidence that SOS1 is phosphorylated by
ABL on Y1196. This post-translational modiﬁcation endows SOS1
with the capacity to activate RAC in response to physiological
stimulation of RTKs and in BCR-ABL pathological context. In the
former, case an RTK-ABL-pY1196-SOS1 pathway operates to
control RAC-mediated actin-based protrusions leading to
enhanced directed migration, consistent with a role of ABL and
RAC in these processes.42,43 A BCR-ABL-pY1196SOS1-RAC axis is
instead critical to promote full transforming and leukemogenic
ability of the fusion protein.
Our ﬁndings are of relevance both for the understanding of the
molecular mechanisms through which SOS1 RAC-GEF activity is
controlled and further unveil an unexpected role of SOS1-RAC in
BCR-ABL transformation. How SOS1 acquires RAC-GEF activity has
remained elusive and difﬁcult to reconcile with the ﬁnding that
the isolated DH-PH domain of SOS1 folds into a catalytically
inactive conformation.22,37 A substantial conformational change of
the DH-PH domain must occur for SOS1 to become catalytically
proﬁcient. Our ﬁndings suggest that phosphorylation of Y1196
may be a way to promote such structural rearrangements.
Consistently, we found that the isolated proline–rich region binds
directly to the DH domain through residues encompassing Y1196.
In addition, phosphorylation of Y1196 reduces this interaction,
induces SOS1 RAC-GEF in vitro and is required to elevate RAC-GTP
levels in vivo. Thus, although we cannot exclude that Y1196 might
be the binding site of yet-to-be found regulators of SOS1, a
plausible possibility is that phosphorylation of this tyrosine is
necessary to liberate an inhibitory molecular proline-rich/DH-PH
interaction. The latter interaction may not necessarily occur intra-
molecularly and might drive the formation of inter-molecular
interactions. Within this context, ABL-mediated phosphorylation of
Y1196 disrupt this linkage, leading to liberation of monomeric
SOS1, which may, in turn, become incorporated into large
macromolecular complex, necessary for full activation of its
RAC1 GEF. Indeed, we have previously shown that one additional
way to modulate SOS1 RAC-GEF is via assembly into a
macromolecular complex that contains EPS8 and ABI1.12,18,19
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Figure 5. Sos1 deletion abolishes BCR-ABL induced transformation of HSCs in vitro and delays leukemogenesis in vivo. (a) 5-FU enriched
BMDCs were retrovirally-infected with pMigBCR-ABLp210 before being treated with (SOS1KO) or without (SOS1ﬂ/ﬂ) tamoxifen and transplanted
into lethally irradiated recipient mice. Recipient mice were injected i.p. with tamoxifen or solvent for 2 days after TX to induce Sos1 deletion
and monitored for leukemia induction. Tamoxifen had no effect on cell engraftment or leukemic development (not shown). In addition, it did
not affect the efﬁciency of infection, which was about 20% in the presence or the absence of TX (not shown). Kaplan–Meier plot details the
overall survival of transplanted mice (n= 6) of 2 independent experiments. P-value was determined by log-rank test. (b and c). Peripheral
blood measurement of mice that received a Sos1 deleted BMDC transplant showed a signiﬁcantly reduction in leukemic white blood cells (b)
gain, as well as a reduced leukemic burden (c) of Sos1 deleted BMDCs transplanted mice during the course of disease. Results are from a
representative transplantation experiment (n= 6) out of two independent ones at the indicated time points. Leukemic burden was measured
by the percentage of enhanced green ﬂuorescent protein (EGFP)-positive CD45 cells in the PB. P-values were determined by Student’s t-test:
*Po0.05, **Po0.01 and ***Po0.005.
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Intriguingly, the latter protein is an interactor and activator of
ABL,44,45 suggesting that SOS1 tyrosine phosphorylation may
ensue following the assembly of this complex. In keeping with this
notion, preliminary evidence indicates that ABL co-
immunoprecipates with SOS1 and EPS8 in an ABI1-dependent
manner. Under this condition, ABL activity is elevated and SOS1
becomes phosphorylated on tyrosine: an event that might be
critical for promoting the RAC-GEF activity of the macromolecular
complex.
Biochemical and genetic studies in mice models have unequi-
vocally shown that the RAC GTPases are critical downstream
signaling targets used by BCR-ABL to promote its full leukemo-
genic and transforming potential.25,28,29,40,46 Mechanistically, the
GEFs VAV1, 2 and 3 have been shown to biochemically link BCR-
ABL to RAC proteins.47 Indeed, VAV proteins are tyrosine
phosphorylated and activated by ABL.42,47,48 Their genetic loss,
however, results in complex BCR-ABL-dependent pathological
phenotypes and delays, but does not abrogate BCR-ABL
leukemogenesis,49 suggesting that other GEFs must have impor-
tant roles. Our ﬁndings are consistent with the latter notion by
showing that SOS1 is one additional critical exchange factors
mediating BCR-ABL-dependent activation of RAC proteins and
transforming ability. In none of our assays, we could distinguish
whether tyrosine phosphorylated SOS1 displays any preference
for the different RAC proteins. However, it would not be unfeasible
that different GEFs target speciﬁc GTPases (different RACs in this
case), in turn required to control a deﬁne set of biological outputs.
In support of this contention, we noticed, that both RAC2 and
VAV3 deﬁciency reduced cell proliferation and increased apopto-
sis, possibly interfering with phosphorylation of the pro-apoptotic
BAD protein.40,49 Loss of Sos1 instead reduces cell proliferation,
but has no effect on apoptosis, while pushing K562 cells to acquire
expression of hemoglobin. K562 cells are bipotent progenitor cells,
which are blocked in the differentiation program due to the
expression of the BCR-ABL.50 Thus, removal of SOS1 may induce
these cells to acquire erythrocyte lineage properties, suggesting
that SOS1 is required for cell proliferation and possibly for the
maintenance of a more undifferentiated state rather than
controlling apoptosis.
In summary, our data reveal a novel molecular mechanism
through which the poorly studied SOS1 RAC-GEF activity becomes
activated by BCR-ABL, contributing to its pathogenic, transforming
functions. They further suggest that targeting this interaction and
signaling axis might be beneﬁcial in combination with BCR-ABL
pharmacological treatment to prevent or delay the onset of BCR-
ABL resistance, at least in part, by reducing the proliferation
potential of leukemic progenitors.
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